Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
45
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
News
FDA Expert Panel Calls for Revision of Menopausal Hormone Therapy Warning Labels
An FDA expert panel convened to reassess boxed warnings for menopausal hormone therapy, with multiple experts arguing that current labels overstate risks and are not supported by comprehensive scientific evidence.
FDA Issues Warning to Mayne Pharma for Misleading Nextstellis Birth Control Safety Claims
The FDA's Office of Prescription Drug Promotion has cited Mayne Pharma for making misleading safety claims about its oral contraceptive Nextstellis in promotional materials.
Sol-Gel and Mayne Pharma Announce $16 Million Deal for EPSOLAY and TWYNEO Rights in the U.S.
• Sol-Gel Technologies has entered into a $16 million agreement with Mayne Pharma for the sale and exclusive license of U.S. rights to dermatology products EPSOLAY and TWYNEO, extending the company's cash runway into Q1 2027. • The transaction allows Sol-Gel to focus resources on its promising SGT-610 program for Gorlin syndrome, which has completed 80% patient recruitment for Phase III trials with top-line results expected in Q4 2026. • Based on recent market research, Sol-Gel estimates SGT-610's U.S. market potential between $400-500 million annually as the first potential preventative treatment for basal cell carcinomas in Gorlin syndrome patients.
North Carolina Emerges as Global Bioscience Hub with $2.5B International Investment Surge
North Carolina has attracted 71 international life science companies from 20 countries, generating over $2.5 billion in investments and creating 17,000 jobs in the past five years.